The FDA says it can't conclude that Novartis' (NYSE:NVS) multiple sclerosis drug Gilenya was connected to the unexplained deaths of patients, although the agency is still worried about the ...
PARIS (Reuters) - Sanofi reported positive results from a late-stage trial of its Aubagio multiple sclerosis drug, bolstering its chances of approval by regulators as it seeks to catch up with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback